Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)
China · Delayed Price · Currency is CNY 3.760
+0.160 (4.44%)
Feb 3, 2026, 3:04 PM CST
SHE:000078 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 27,175 | 30,214 | 36,310 | 37,759 | 40,926 | 39,935 |
Other Revenue | 102.93 | 102.93 | 108.77 | 76.08 | 127.23 | 87.59 |
| 27,278 | 30,317 | 36,419 | 37,835 | 41,054 | 40,022 | |
Revenue Growth (YoY) | -15.63% | -16.75% | -3.74% | -7.84% | 2.58% | -3.54% |
Cost of Revenue | 24,895 | 27,486 | 32,901 | 34,059 | 36,660 | 35,383 |
Gross Profit | 2,382 | 2,832 | 3,518 | 3,776 | 4,394 | 4,640 |
Selling, General & Admin | 2,018 | 2,243 | 2,540 | 2,680 | 2,709 | 2,727 |
Research & Development | 37.44 | 37.89 | 47.79 | 48.29 | 39.19 | 38.11 |
Other Operating Expenses | 109.57 | 94.58 | 103.65 | 102.17 | 114.22 | 53.53 |
Operating Expenses | 2,497 | 2,655 | 2,899 | 3,011 | 2,934 | 2,844 |
Operating Income | -115.18 | 176.9 | 618.73 | 764.95 | 1,460 | 1,796 |
Interest Expense | -704.26 | -808.77 | -945.94 | -930.86 | -875.54 | -959.4 |
Interest & Investment Income | 118.38 | 55.74 | 48.79 | 65.47 | 131.55 | 108.86 |
Currency Exchange Gain (Loss) | 0 | 0 | 0 | 0 | -1.64 | -0.39 |
Other Non Operating Income (Expenses) | -47.78 | -55.43 | -262.09 | -192.05 | -36.75 | -151.73 |
EBT Excluding Unusual Items | -748.85 | -631.57 | -540.51 | -292.48 | 677.31 | 792.88 |
Impairment of Goodwill | -477.78 | -477.78 | -875.96 | -523.77 | -183.67 | -578.77 |
Gain (Loss) on Sale of Investments | 1.21 | 6.38 | -27.67 | -86.66 | 37.71 | 57.06 |
Gain (Loss) on Sale of Assets | 0.48 | 6.81 | 3.24 | 11.33 | 0.22 | 1.21 |
Asset Writedown | 10.28 | - | -51.43 | -12.66 | -9.59 | -1.05 |
Other Unusual Items | 31.99 | 14.46 | 33.86 | 51.08 | 54.32 | -3.89 |
Pretax Income | -1,183 | -1,082 | -1,458 | -853.16 | 576.31 | 267.44 |
Income Tax Expense | 42.24 | 85.62 | 260.56 | 138.29 | 318.44 | 308.73 |
Earnings From Continuing Operations | -1,225 | -1,167 | -1,719 | -991.45 | 257.87 | -41.29 |
Minority Interest in Earnings | 10.99 | -26.1 | 29.09 | -35.52 | -164.57 | -247.24 |
Net Income | -1,214 | -1,193 | -1,690 | -1,027 | 93.3 | -288.53 |
Net Income to Common | -1,214 | -1,193 | -1,690 | -1,027 | 93.3 | -288.53 |
Shares Outstanding (Basic) | 2,629 | 2,631 | 2,631 | 2,630 | 2,628 | 2,623 |
Shares Outstanding (Diluted) | 2,629 | 2,631 | 2,631 | 2,630 | 2,628 | 2,623 |
Shares Change (YoY) | 3.50% | -0.00% | 0.05% | 0.07% | 0.19% | -0.87% |
EPS (Basic) | -0.46 | -0.45 | -0.64 | -0.39 | 0.04 | -0.11 |
EPS (Diluted) | -0.46 | -0.45 | -0.64 | -0.39 | 0.04 | -0.11 |
Free Cash Flow | -82.26 | -45.06 | -514.26 | -158.65 | 736.89 | 1,503 |
Free Cash Flow Per Share | -0.03 | -0.02 | -0.20 | -0.06 | 0.28 | 0.57 |
Gross Margin | 8.73% | 9.34% | 9.66% | 9.98% | 10.70% | 11.59% |
Operating Margin | -0.42% | 0.58% | 1.70% | 2.02% | 3.56% | 4.49% |
Profit Margin | -4.45% | -3.94% | -4.64% | -2.71% | 0.23% | -0.72% |
Free Cash Flow Margin | -0.30% | -0.15% | -1.41% | -0.42% | 1.80% | 3.76% |
EBITDA | 30 | 344.64 | 816.55 | 939.14 | 1,633 | 1,990 |
EBITDA Margin | 0.11% | 1.14% | 2.24% | 2.48% | 3.98% | 4.97% |
D&A For EBITDA | 145.19 | 167.75 | 197.82 | 174.19 | 172.97 | 194.29 |
EBIT | -115.18 | 176.9 | 618.73 | 764.95 | 1,460 | 1,796 |
EBIT Margin | -0.42% | 0.58% | 1.70% | 2.02% | 3.55% | 4.49% |
Effective Tax Rate | - | - | - | - | 55.25% | 115.44% |
Revenue as Reported | 27,278 | 30,317 | 36,419 | 37,835 | 41,054 | - |
Advertising Expenses | - | 10.74 | 25.17 | 41.15 | 77.05 | 80.85 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.